Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Vaccine Inoculations Show No Link to Autism, Other Health Problems: Presented at IDSA - (DGDispatch)
    Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents - (JAMA)
    Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight Gain - (DGNews)
    The Clinical Course of Advanced Dementia - (N Engl J Med)
    Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Psychiatry Other

    Webcasts/CME archive

     Recent cases - Psychiatry Other
      Female Sexual Dysfunction as a Comorbid Illness
      11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
      Comorbidity of Asperger's Syndrome and Bipolar Disorder
      Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
      Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

      Cases archive
        




      my personal edition > psychiatry other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Once-Daily Atomoxetine Achieves Continuous Symptom Relief in Attention Deficit/Hyperactivity Disorder: Presented at APA

      By Bruce Sylvester

      SAN FRANCISCO, CA -- May 25, 2003 -- Once-daily atomoxetine offers safe, rapid, and continuous symptom relief to children with attention deficit/hyperactivity disorder (ADHD).

      The efficacy of once-daily atomoxetine lasts throughout the day, into the evening and early morning, researchers reported here on May 23rd at the 156th Annual Meeting of the American Psychiatric Association.

      "We saw higher efficacy earlier in the child's day when they need it most, and also lasting through the evening and sleeping hours, without a big drop-off effect prior to the next dosing," said investigator and presenter Douglas Kelsey, MD, PhD, clinical researcher, department of neuroscience, Eli Lilly and Co., Indianapolis, Indiana, United States. "In particular, the onset of symptom relief when it is generally most needed -- the first part of the day and school day -- suggests a distinctive role for this formulation in helping children be well and more successful."

      A group of 197 children, aged 6-12 years and diagnosed with ADHD, were randomized in a 2:1 ratio to 8 weeks of once-daily atomoxetine or placebo.

      The researchers evaluated the efficacy of symptom treatment using parent- and investigator-rating scales. Parental assessments of children's evening and early morning home behaviors were gathered using the Daily Parent Rating of Evening and Morning Behavior-Revised (DPREMB-R) and the Conners' Global Index: Parent Evening Scale (CGI-PE).

      Results showed that once-daily atomoxetine at a final mean daily dose of 1.3 mg/kg was significantly more effective than placebo in treating core symptoms. Efficacy outcomes into the evening hours in active treatment patients were superior to those of placebo-treated patients as assessed by the DPREMB-R and CGI-PE.

      The DPREMB-R showed a significant reduction of symptoms in the morning, and an onset of effect that was significantly different from that of placebo after the first day on medication. Discontinuations due to adverse events were less than 5% for both groups.

      "This is very good news for these children," Dr. Kelsey noted. "But imagine what this also means to a parent who can now help his or her child start strong and remain stable throughout the day, with only one moment in each day to think about taking medication."

      This research was funded by Eli Lilly and Co.


      [Study title: Once-Daily Atomoxetine in Childhood ADHD: Continuous Symptom Relief. Abstract NR716]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send